Latest Breaking News On - Sosei heptare - Page 1 : comparemela.com

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,

United kingdomCity ofSoult ukpyolsiSouth koreaNew yorkUnited statesRheinland pfalzSosei heptaresErica hollingsworthKentaro taharaFrazer hallSosei heptareLinda ruckelReinhard malinShinichiro nishishitaMaya bennison

Boehringer, Sosei Ink Potential $732M Deal for Schizophrenia Treatment

Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.

United kingdomCity ofMatt barnesSosei heptaresHugh marstonSosei heptareJapan sosei group corporationRibocure pharmaceuticalsBoehringer ingelheimSosei group corporationHeptares therapeuticsSuzhou robi life science

Sosei and PharmEnable extend neurological disease drugs hunt | Business Weekly | Technology News | Business news

Sosei and PharmEnable extend neurological disease drugs hunt | Business Weekly | Technology News | Business news
businessweekly.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessweekly.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomMatt barnesSosei heptareNeurocrine biosciencesGenentech rocheSosei heptaresMitsubishi tanabe pharma groupJapanese biopharmaPharmenable therapeuticsStructure based drug designHeptares therapeuticsHannah soreVenture management

Sosei Heptares Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Sosei Heptares Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomSoult ukpyolsiSouth koreaErica hollingsworthMaya bennisonNeurocrine biosciencesMatt barnesFrazer hallShinichiro nishishitaSosei heptaresKentaro taharaSosei heptareSosei group corporation the companyTokyo stock exchangeMedistrava consulting for international media

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofSoult ukpyolsiSouth koreaDisclosuresmaya bennisonRelationskentaro taharaSosei heptareGsksosei heptaresShinichiro nishishitaFrazer hallSosei heptaresErica hollingsworthChris cargillCommunications managerSosei groupRegulatory agency